2025 Arnold Caplan Award RECLAIM: A Translational Platform for Cartilage Repair and Musculoskeletal Tissue Regeneration Using Allogeneic MSCs

Cartilage defects remain a prevalent and challenging clinical problem, especially in young, active individuals. Existing treatments such as microfracture or autologous chondrocyte implantation either lack durability or require multiple surgeries and extensive cell culture. To address these limitations, we developed RECLAIM-a one-stage, two-cell-type procedure combining allogeneic mesenchymal stromal cells and autologous chondrons. RECLAIM harnesses the trophic and immunomodulatory properties of MSCs to stimulate autologous chondron-driven tissue repair, minimizing invasiveness while optimizing biologic regeneration. This article reviews the preclinical discovery, clinical translation, trial results, and platform potential of RECLAIM, which was recognized with the 2025 Arnold I. Caplan Award for Distinguished Research in OrthoBiologics. Our work builds on Professor Caplan's pioneering conceptualization of MSCs as "medicinal signaling cells" and establishes a model for academic, investigator-driven translation of regenerative science into clinical practice.

Authors

Institutions

Publication Details

Journal
Journal of the American Academy of Orthopaedic Surgeons
Published
2025-10-08
DOI
https://doi.org/10.5435/jaaos-d-25-01041
Primary Topic
Osteoarthritis Treatment and Mechanisms
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

2025 Arnold Caplan Award RECLAIM: A Translational Platform for Cartilage Repair and Musculoskeletal Tissue Regeneration Using Allogeneic MSCs

Daniël B.F. Saris
Journal of the American Academy of Orthopaedic Surgeons
Osteoarthritis Treatment and Mechanisms
article

2025 Arnold Caplan Award RECLAIM: A Translational Platform for Cartilage Repair and Musculoskeletal Tissue Regeneration Using Allogeneic MSCs

Daniël B.F. Saris
article en

Abstract

Cartilage defects remain a prevalent and challenging clinical problem, especially in young, active individuals. Existing treatments such as microfracture or autologous chondrocyte implantation either lack durability or require multiple surgeries and extensive cell culture. To address these limitations, we developed RECLAIM-a one-stage, two-cell-type procedure combining allogeneic mesenchymal stromal cells and autologous chondrons. RECLAIM harnesses the trophic and immunomodulatory properties of MSCs to stimulate autologous chondron-driven tissue repair, minimizing invasiveness while optimizing biologic regeneration. This article reviews the preclinical discovery, clinical translation, trial results, and platform potential of RECLAIM, which was recognized with the 2025 Arnold I. Caplan Award for Distinguished Research in OrthoBiologics. Our work builds on Professor Caplan's pioneering conceptualization of MSCs as "medicinal signaling cells" and establishes a model for academic, investigator-driven translation of regenerative science into clinical practice.

Journal of the American Academy of Orthopaedic SurgeonsVol. 33(23)
Mayo Clinic (US), Mayo Clinic in Arizona (US)
Openalex Percentile: Top 58%
Osteoarthritis Treatment and Mechanisms
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.